Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Keymed BiosciencesFRA:64Z +1.81%44 Days Inventory is 600.98 as of Dec. 2025, which is 5% below its 10-year median of 629.41. GuruFocus rates FRA:64Z with a GF Score™ of 44/100 and a GF Value™ of €18.34 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 638 Biotechnology companies, Keymed Biosciences ranks worse than 86.52% on this metric.
The historical rank and industry rank for Keymed Biosciences's Days Inventory or its related term are showing as below:
FRA:64Z'
s Days Inventory Range Over the Past 10 Years
Min: 244.26 Med: 629.41 Max: 4409.9
Current: 646.61
During the past 7 years, Keymed Biosciences's highest Days Inventory was 4409.90. The lowest was 244.26. And the median was 629.41.
FRA:64Z's Days Inventory is ranked worse than 86.52% of 638
companies
in the Biotechnology industry
Industry Median: 181.695
vs FRA:64Z: 646.61
Keymed Biosciences's Days Inventory
declined
from Dec. 2024 (2,085.02) to Dec. 2025 (600.98).
Inventory Turnover measures how fast the company turns over its inventory within a year.
Keymed Biosciences's Inventory Turnover for the
six
months ended in Dec. 2025 was 0.30.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Keymed Biosciences's Inventory-to-Revenue for the
six
months ended in Dec. 2025 was 0.83.
Keymed Biosciences (FRA:64Z) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Keymed Biosciences's Inventory Turnover for the
six
months ended in Dec. 2025 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Keymed Biosciences's Inventory to Revenue for the
six
months ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Keymed Biosciences Days Inventory Related Terms
Keymed Biosciences Days Inventory Historical Data
* Premium members only.
The historical data trend for Keymed Biosciences's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:64Z vs VRTX, REGN, RVMD: Days Inventory Comparison
For the Biotechnology subindustry, Keymed Biosciences's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Keymed Biosciences Days Inventory vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Keymed Biosciences's Days Inventory distribution charts can be found below:
* The bar in red indicates where Keymed Biosciences's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Keymed Biosciences (FRA:64Z) has a Days Inventory of 600.98 as of Dec. 2025. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Keymed Biosciences and its competitors. This is near median its historical median of 629.41. Over the past decade, Keymed Biosciences' Days Inventory has ranged from 244.26 to 4,409.90. According to the industry distribution chart, Keymed Biosciences ranks #552 out of 638 companies in the Biotechnology industry, placing it in the top 86.5%.
Is Keymed Biosciences' Days Inventory too high?
Keymed Biosciences' current Days Inventory of 600.98 is near median its 10-year median of 629.41. Over the past 10 years, this metric has ranged from a low of 244.26 to a high of 4,409.90. The Biotechnology industry median Days Inventory is 181.70. Keymed Biosciences' value of 600.98 is 230.8% above this industry median. Based on the distribution chart, Keymed Biosciences ranks #552 out of 638 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Keymed Biosciences has a GF Score™ of 44/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Keymed Biosciences' Days Inventory compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Keymed Biosciences ranks #552 out of 638 companies for Days Inventory. This places Keymed Biosciences in the lower half of its industry. The industry median Days Inventory is 181.70. Keymed Biosciences' value of 600.98 is 230.8% above this benchmark. Historically, Keymed Biosciences' own Days Inventory has ranged from 244.26 to 4,409.90 over the past decade. While the company's 10-year median is 629.41 vs. the industry median of 181.70, Keymed Biosciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Biotechnology company?
The median Days Inventory among Biotechnology companies is 181.70, based on 638 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Keymed Biosciences's current Days Inventory of 600.98 is 230.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Keymed Biosciences and its competitors. For the Biotechnology industry, the median Days Inventory is 181.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Keymed Biosciences's current Days Inventory is 600.98, which is near median its own 10-year median of 629.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Keymed Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Keymed Biosciences (FRA:64Z) is currently considered Possible Value Trap. The stock's GF Value™ is €18.34, compared to a current price of €8.45 — trading 53.9% below its estimated fair value. The current Days Inventory is 600.98, which is near median its 10-year median of 629.41 and 230.8% above the Biotechnology industry median of 181.70. Keymed Biosciences' overall GF Score™ is 44/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Keymed Biosciences (FRA:64Z), the current Days Inventory is 600.98 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Keymed Biosciences (FRA:64Z) Overvalued in 2026?
Based on GuruFocus' analysis, Keymed Biosciences stock appears to be undervalued.
The current stock price of €8.45 is trading 53.9% below its estimated GF Value™ of €18.34.
GuruFocus considers Keymed Biosciences to be Possible Value Trap.
Key valuation signals for FRA:64Z:
Days Inventory: 600.98 (near median its 10-year median of 629.41)
GF Value™: €18.34 vs. price of €8.45 (53.9% below fair value)
Industry Position: 230.8% above the Biotechnology median (#552 of 638)
No single metric tells the full story. See the FRA:64Z stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Keymed Biosciences Inc is a biotechnology company with multiple clinical-stage assets. The company is focused on the in-house discovery and development of biological therapies that address large underserved medical needs in the autoimmune and oncology therapeutic areas. Its clinical-stage drug candidates include CM310, CM326, CM313, and CM336 among others. The company is engaged in biopharmaceutical research and development, which is regarded as a single reportable segment. Geographically, it generates a majority of its revenue from overseas markets and the rest from Mainland China.
44GF Score
Get the complete analysis for FRA:64Z
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:64Z has been successfully added to your 
